Investigational Drug Information for Omecamtiv mecarbil
✉ Email this page to a colleague
What is the development status for investigational drug Omecamtiv mecarbil?
Omecamtiv mecarbil is an investigational drug.
There have been 11 clinical trials for Omecamtiv mecarbil.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 9th 2019.
The most common disease conditions in clinical trials are Heart Failure, Ventricular Dysfunction, Left, and Systolic Murmurs. The leading clinical trial sponsors are Cytokinetics, Amgen, and Servier.
There are thirty-four US patents protecting this investigational drug and three hundred and eighty-nine international patents.
Summary for Omecamtiv mecarbil
| US Patents | 34 |
| International Patents | 389 |
| US Patent Applications | 159 |
| WIPO Patent Applications | 126 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 3 (2019-04-09) |
| Vendors | 56 |
Recent Clinical Trials for Omecamtiv mecarbil
| Title | Sponsor | Phase |
|---|---|---|
| Omecamtiv Mecarbil Post-trial Access Study | Amgen | Phase 3 |
| Omecamtiv Mecarbil Post-trial Access Study | Cytokinetics | Phase 3 |
| Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults | Amgen | Phase 1 |
Clinical Trial Summary for Omecamtiv mecarbil
Top disease conditions for Omecamtiv mecarbil
Top clinical trial sponsors for Omecamtiv mecarbil
US Patents for Omecamtiv mecarbil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Omecamtiv mecarbil | ⤷ Sign Up | Compounds, compositions and methods | Cytokinetics, Incorporated (South San Francisco, CA) | ⤷ Sign Up |
| Omecamtiv mecarbil | ⤷ Sign Up | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| Omecamtiv mecarbil | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Omecamtiv mecarbil | ⤷ Sign Up | Fused imidazole derivatives as IDO/TDO inhibitors | SciFluor Life Sciences, Inc. (Cambridge, MA) | ⤷ Sign Up |
| Omecamtiv mecarbil | ⤷ Sign Up | Compounds for the inhibition of indoleamine-2,3-dioxygenase | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| Omecamtiv mecarbil | ⤷ Sign Up | Compounds, compositions and methods | CYTOKINETICS, INC. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Omecamtiv mecarbil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Omecamtiv mecarbil | Argentina | AR053405 | 2024-06-17 | ⤷ Sign Up |
| Omecamtiv mecarbil | Australia | AU2005264988 | 2024-06-17 | ⤷ Sign Up |
| Omecamtiv mecarbil | Brazil | BRPI0512193 | 2024-06-17 | ⤷ Sign Up |
| Omecamtiv mecarbil | Canada | CA2570999 | 2024-06-17 | ⤷ Sign Up |
| Omecamtiv mecarbil | China | CN101035525 | 2024-06-17 | ⤷ Sign Up |
| Omecamtiv mecarbil | Cyprus | CY1115716 | 2024-06-17 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
